Shares cratered 61.7% to $0.49 after the FDA ruled that Echo IQ's AI-powered heart failure detection software is not "substantially equivalent" to an existing approved device — the standard required under the 510(k) clearance pathway. The determination means the application has not been cleared for commercial use. The sell-off vaporized hundreds of millions in market value from a stock that had ridden a wave of hype around AI-driven cardiac diagnostics.
• Strong Clinical Data Wasn't Enough to Satisfy Regulators. The validation study, run on 17,000 echocardiograms from the Mayo Clinic, showed sensitivity of 99.5% and specificity of 91.0% in detecting heart failure. Those are impressive numbers — but the FDA's 510(k) process isn't just about accuracy. It requires devices to demonstrate they are "substantially equivalent" in safety and effectiveness to a legally marketed device. Echo IQ evidently failed to convince the agency on that comparison. The software failed to secure clearance in its current form, and we don't yet know why or what work remains.
• The Heart Failure Market Was the Big Prize. Heart failure is the leading cause of rehospitalization in the U.S., accounts for 17% of all healthcare spending, and represents a total market of US$60 billion.
The heart failure opportunity was far larger than Echo IQ's existing aortic stenosis product, partly because it could piggyback off an existing insurance reimbursement code. Without clearance, that entire revenue runway is now indefinitely delayed.
• The Company Has Cash, But the Clock Is Ticking. Echo IQ reported cash reserves exceeding $105 million as of July 2026 , giving it a long financial runway to resubmit or pursue alternative regulatory paths. The ruling does not affect the already FDA-cleared aortic stenosis platform or its U.S. commercialization efforts , so the company retains a functioning business. But with the stock down more than 60%, the cost of any future equity raise just soared.
• Index Inclusion Adds an Unusual Wrinkle. Echo IQ was recently announced for inclusion in the ASX 300, meaning index funds will soon be mandated to buy the stock. That could provide a floor of passive demand, but it will also make more stock available to short sellers — and the short position, previously under 0.35%, is expected to grow.
The investor webinar scheduled for September 9 will be management's first chance to explain what specifically the FDA objected to and whether a resubmission or a more burdensome "de novo" review is the likely next step. Until then, the market is pricing in the worst case: that the company's biggest growth story just hit a wall.